ERBB2 and gastric cancer: These results need to be validated in larger cohorts as well as in combination with other drug agents, which led to the development of the following trials: the phase-III DESTINY-Gastric04 trial (NCT04704934), comparing second-line T-DXd to the standard of care ramucirumab + paclitaxel in a large GEA cohort and the phase-Ib/II DESTINY-Gastric03 trial (NCT04379596), which aims to assess the safety and efficacy of T-DXd with different combinations including immunotherapy, CHT or both in advanced HER2 expressing GC [44,45].